BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, Farci P, O'Brien CB, Lardelli P, Blotner S. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. 2006;44:679-685. [PMID: 16487620 DOI: 10.1016/j.jhep.2006.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Hsu CS, Liu CJ, Liu CH, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2008;2:250-7. [PMID: 19669312 DOI: 10.1007/s12072-008-9064-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
2 Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diagnostic Microbiology and Infectious Disease 2008;61:408-14. [DOI: 10.1016/j.diagmicrobio.2008.03.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
3 Méndez-sánchez N, Gadano A, Alves de Mattos A, Soza A, Claudio AM, Galoppo M, Kershenobich D, Strauss E, Fassio E, Castañeda G, Valladares G, Coelho HSM, Daruich J, Garassini M, Dávalos M, Uribe M, Rodriguez-torres M, Zapata R, Arrese M, Sánchez-ávila F, Dehesa M, Padilla FB, Lerias de Almeida PR, Pessoa M, Torres-ibarra R, Hevia F, Contreras M, Cheinquer H. Latin American Association for the Study of the Liver Practice Guidelines. Annals of Hepatology 2010;9:S8-S26. [DOI: 10.1016/s1665-2681(19)31718-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Wang CC, Lim LY, Deubner H, Tapia K, Lau AW, Manansala J, Krows M, Shuhart MC, Kowdley KV. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol. 2008;42:820-826. [PMID: 18458642 DOI: 10.1097/mcg.0b013e318156feef] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
5 Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat. 2012;19:e48-e57. [PMID: 22239526 DOI: 10.1111/j.1365-2893.2011.01535.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
6 Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Dai CY, Yu ML. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int 2013;7:162-70. [PMID: 26201630 DOI: 10.1007/s12072-012-9388-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
8 Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829-834. [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
9 Xu CJ, Zhang CP, Wang XH, Liu LJ, Zhou SS, Wang JH, He QJ, Wang YZ, Guo WS, Zhu WB, Jiang Y. An individualized strategy for treatment of hepatitis C virus carriers with normal aminotransferase levels: Analysis of 73 cases. Shijie Huaren Xiaohua Zazhi 2014; 22(16): 2317-2322 [DOI: 10.11569/wcjd.v22.i16.2317] [Reference Citation Analysis]
10 Loftis JM, Taylor J, Raué HP, Slifka MK, Huang E. Alcohol intake alters immune responses and promotes CNS viral persistence in mice. Behav Brain Res 2016;312:1-8. [PMID: 27269869 DOI: 10.1016/j.bbr.2016.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Amadoz A, González-Candelas F. A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data. Evol Bioinform Online 2015;11:15-24. [PMID: 25780333 DOI: 10.4137/EBO.S20853] [Reference Citation Analysis]
12 Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007;45:2426-33. [PMID: 17537941 DOI: 10.1128/JCM.02448-06] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
13 Jin YJ, Shim JH, Kim GA, Yu E, Kim KM, Lim YS, Lee HC. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. BMJ Open 2014;4:e006255. [PMID: 25431223 DOI: 10.1136/bmjopen-2014-006255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Persico M, Masarone M, Mura VL, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. World J Gastroenterol 2009; 15(4): 462-466 [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
15 Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, Chen TH, Cheng ML, Chang KC, Chiu CT, Yeh CT, Pang JH, Shiao MS. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS One. 2014;9:e104783. [PMID: 25122116 DOI: 10.1371/journal.pone.0104783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
16 Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, Hara M, Iwane S, Takahashi H, Akiyama T. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213-220. [PMID: 18710430 DOI: 10.1111/j.1478-3231.2008.01853.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
17 Kobayashi Y, Kawaguchi Y, Mizuta T, Kuwashiro T, Oeda S, Oza N, Takahashi H, Iwane S, Eguchi Y, Anzai K. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol. 2011;46:529-535. [PMID: 21046172 DOI: 10.1007/s00535-010-0338-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
18 Hsu CS, Hsu SJ, Lin HH, Tseng TC, Wang CC, Chen DS, Kao JH. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. J Formos Med Assoc. 2014;113:716-721. [PMID: 24974131 DOI: 10.1016/j.jfma.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med 2014;47:233-41. [PMID: 25145616 DOI: 10.1016/j.amepre.2014.05.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
20 Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol. 2011;55:1187-1194. [PMID: 21703195 DOI: 10.1016/j.jhep.2011.03.010] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
21 Abdel-rahman M, Saad Y, El-raziky M, Zayed N, El-akel W, Said M, El-beshlawy M, Esmat G. Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. Clinics and Research in Hepatology and Gastroenterology 2013;37:479-84. [DOI: 10.1016/j.clinre.2013.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
22 Zapata R. Clinical aproach to the patient with chronic hepatitis C infection and normal aminotransferases. Annals of Hepatology 2010;9:S72-9. [DOI: 10.1016/s1665-2681(19)31728-4] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010;51:1577-83. [PMID: 20162730 DOI: 10.1002/hep.23505] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 10.0] [Reference Citation Analysis]
24 Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009;15:462-6. [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Okanoue T, Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, Takehara T, Kumada T, Tanaka E, Nishiguchi S, Izumi N, Sata M, Onji M, Yamada G, Okita K, Kumada H. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatology Research 2008;38:27-36. [DOI: 10.1111/j.1872-034x.2007.00217.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
26 Lopes EP, Sette LH, Sette JB, Luna CF, Andrade AM, Moraes M, Sette PC, Menezes R, Cavalcanti RL, Conceição SC. Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session. Clinics (Sao Paulo) 2009;64:941-5. [PMID: 19841699 DOI: 10.1590/S1807-59322009001000002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
27 Tu WH, Zhu WJ, Qian F, Zhang JM, Zhu CW. Necessity of lowering the upper limit of normal of alanine aminotransferase in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2018; 26(30): 1765-1771 [DOI: 10.11569/wcjd.v26.i30.1765] [Reference Citation Analysis]
28 Harrison SA. HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome. J Hepatol 2006;44:624-6. [PMID: 16503073 DOI: 10.1016/j.jhep.2006.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Valenti L, Pelusi S, Aghemo A, Gritti S, Pasulo L, Bianco C, Iegri C, Cologni G, Degasperi E, D'Ambrosio R, Del Poggio P, Soria A, Puoti M, Carderi I, Pigozzi MG, Carriero C, Spinetti A, Zuccaro V, Memoli M, Giorgini A, Viganò M, Rumi MG, Re T, Spinelli O, Colombo MC, Quirino T, Menzaghi B, Lorini G, Pan A, D'Arminio Monforte A, Buscarini E, Autolitano A, Bonfanti P, Terreni N, Aimo G, Mendeni M, Prati D, Lampertico P, Colombo M, Fagiuoli S; NAVIGATORE-Lombardia Network. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. Hepatol Commun 2021. [PMID: 34811949 DOI: 10.1002/hep4.1851] [Reference Citation Analysis]
30 Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Am J Gastroenterol 2008;103:3159-66. [PMID: 18786125 DOI: 10.1111/j.1572-0241.2008.02159.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
31 Tural C, Planas R, Sirera G, Clotet B. Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. Curr Opin HIV AIDS 2007;2:496-502. [PMID: 19372933 DOI: 10.1097/COH.0b013e3282f0dce1] [Reference Citation Analysis]
32 Morisco F, Pagliaro L, Caporaso N, Bianco E, Sagliocca L, Fargion S, Smedile A, Salvagnini M, Mele A. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis. 2008;40:585-598. [PMID: 18395501 DOI: 10.1016/j.dld.2008.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
33 Sinn DH, Gwak GY, Shin JU, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World J Gastroenterol 2013; 19(14): 2256-2261 [PMID: 23599653 DOI: 10.3748/wjg.v19.i14.2256] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Hsu C, Hsu S, Chen H, Liu C, Jeng J, Liu C, Chen P, Chen D, Kao J. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int 2013;7:171-9. [DOI: 10.1007/s12072-012-9390-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
35 Hsu CS, Hsu SJ, Liu WL, Chen DS, Kao JH. Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. Sci Rep. 2016;6:32303. [PMID: 27561198 DOI: 10.1038/srep32303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
36 Alavian SM, Miri SM, Tabatabaei SV, Keshvari M, Behnava B, Elizee PK, Mahboobi N, Lankarani KB. Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients. Gut Liver 2011;5:348-55. [PMID: 21927665 DOI: 10.5009/gnl.2011.5.3.348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]